The intravenous drug represents a new treatment for relapsing forms of MS and the first treatment for primary progressive MS — the most disabling form of the disease.
About 15 percent of MS patients are diagnosed with PPMS, which occurs when a patient’s symptoms steadily worsen with any relapses or remissions, according to the CDC.
Genentech expects Ocrevus to be available in the U.S. by mid-April, according to a company news release.
More articles on supply chain:
7 must-reads for supply chain leaders this week
America’s focus on technology — rather than medicine — is ‘eroding our national intellect,’ says pharma exec
Bill Ackman calls $4B Valeant investment ‘huge mistake’
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
